Is MYGN a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on The Labcorp prenatal sale, with revenue (ttm) at ~$807 million. The bear case rests on reimbursement is the central risk. Analysts covering it are spread from $2.00 to $8.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Reimbursement is the central risk. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $2.00, -65.1% from the $5.73 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

The Labcorp prenatal sale. The $210 million cash sale of Prequel, Foresight, SneakPeek and FirstGene is the main reason MYGN is trending today. The most optimistic analyst target on MYGN is $8.00, +39.6% from the $5.73 price. That figure is only reachable if this thesis works close to its best case.

Reimbursement is the central risk. Myriad's revenue fell ~11% in the second quarter on nearly flat volume, which shows how sensitive it is to what payers actually pay. CMS's proposed 2027 Clinical Laboratory Fee Schedule includes cuts of up to ~15% on some codes Myriad uses; one analyst called the impact minimal, but the final numbers are not set. GeneSight lost UnitedHealthcare coverage in 2025, a reminder that a single payer decision can hit a franchise. The company is losing money: the first half of 2026 produced a ~$77 million GAAP net loss and ~$21 million of negative adjusted EBITDA, with cash down from ~$150 million to ~$115 million in six months. Competition in hereditary testing and MRD comes from larger, better funded labs. The prenatal sale may not close, or may close late, and losing ~$160 million of revenue makes the remaining company smaller and more concentrated. Law firms announced investigations after the July guidance cut; these are solicitations, not filed suits, but they can become one. The stock is highly volatile, with more than 40 daily moves above 5% in the past year. The most pessimistic published target is $2.00, -65.1% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Salt Lake City genetic-testing lab behind the MyRisk hereditary cancer, GeneSight and Prolaris tests.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (The Labcorp prenatal sale) stalling in the reported numbers rather than in the narrative, the risk above (reimbursement is the central risk) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

On October 20, 2026, Myriad Genetics announced a definitive agreement to sell its Prenatal Health testing business, including Prequel, Foresight, SneakPeek and FirstGene, to Labcorp for $210 million in cash plus the value of inventory. Shares jumped more than 20% in early trading, from roughly $4.50 to around $5.50. The size of the deal relative to the company explains the reaction: $210 million equaled about half of Myriad's ~$403 million market value at the prior close. Investors read it as a sign that management's portfolio review is producing results and that the company will have more cash to fund its oncology tests. The deal is expected to close in early 2027 and includes a $10.5 million reverse termination fee. Note that Myriad is the seller here, not the company being acquired, so MYGN does not track a fixed offer price.

Myriad runs clinical laboratories that perform genetic and genomic tests ordered by doctors. Its biggest product line is hereditary cancer testing, led by the MyRisk panel, which checks inherited genes linked to breast, ovarian, colon and other cancers. It also sells Prolaris (prostate cancer aggressiveness), EndoPredict (breast cancer recurrence risk), MyChoice CDx (a companion diagnostic that helps identify patients for PARP inhibitor drugs) and Precise MRD, a blood test that looks for traces of cancer after treatment. GeneSight, its mental health test, analyzes genes that affect how patients process psychiatric drugs. Until the Labcorp sale closes it also owns a prenatal business. The company earns money per test, from insurers, Medicare and patients, so both test volume and the average price collected drive revenue.

The biggest drop came after second-quarter results on July 30, 2026. Revenue fell ~11% to ~$190.7 million, adjusted EPS was a loss of ~$0.25, and management cut full-year revenue guidance to $770 to $790 million while suspending adjusted EBITDA guidance. The stock fell about 46% in the next session. What alarmed investors was the cause: test volume was nearly flat, but the average revenue collected per test fell ~9%, including ~$11 million of lower than expected collections on older claims. That raised questions about the reliability of prior guidance, which management had reaffirmed in May. Several law firms announced investigations afterward. Before October's rally the stock was down about 30% for the year and nearly 50% below its November 2025 high of ~$8.18.